Pharmafile Logo

T-DM1

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

Roche's Perjeta pertuzumab

NICE rejects Roche’s breast cancer drug Perjeta

Says the treatment's long-term benefits are unclear

Focus on immunotherapies: special magazine from Blue Latitude Health

Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear...

Blue Latitude Health

Roche Basel Switzerland

Roche gets first approval for PD-L1 inhibitor Tecentriq

Expects to launch bladder cancer treatment within the next two weeks

Novartis day

Trial sets up showdown between Ibrance and Novartis’ ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval

Novartis building

Novartis splits pharma unit as Epstein exits

Restructure sees creation of standalone cancer arm Novartis Oncology

Deal Watch March 2016

AstraZeneca, Roche, Sanofi and Valeant are featured in this month’s roundup of pharma deals

Sanofi reception

Sanofi hints at sweetened Medivation deal – or hostile bid

CEO Oliver Brandicourt claims “overwhelming support” for deal from shareholders

Sanofi reception

Medivation unimpressed with Sanofi’s offer

CEO says the offer “substantially undervalues” the oncology specialist

Bristol-Myers Squibb (BMS) building

BMS claims 80% market share for Opdivo in US

New indications and label updates boost the cancer immunotherapy’s market position

- PMLiVE

AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal

Continues to build its oncology business to lessen its reliance on Humira

Sanofi reception

Sanofi makes $9.3bn unsolicited bid for Medivation

Hopes to boost oncology business with fast-growing prostate cancer drug Xtandi

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links